
0:00
18:14
Another day, another b cell podcast. Seems to be all the rage! This week I discuss the recently published NEJM trial of the anti CD20 agent obinutuzumab in lupus nephritis. Worth a read and listen, paper can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa2410965
More episodes from "The Evidence Based Rheumatology Podcast"
Don't miss an episode of “The Evidence Based Rheumatology Podcast” and subscribe to it in the GetPodcast app.